Minghui Pharmaceutical and ASKA Sign Potential US$440 Million Licensing Deal for Thyroid Eye Disease Drug in Japan

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement for the ...

November 05, 2026 | Thursday | News
Ambrose Healthcare’s Rare Disease Strategy: Reviving Promising Therapies Through Strategic Acquisitions

Ambrose Healthcare’s acquisition of AM-Pharma, valued at up to €161 million plus royalties, strengthens its rare disease pipeline and establishe...

November 04, 2026 | Wednesday | Interview
Kos Biotechnology Partners Invests in Golden Age Health to Expand Rare Disease Drug Access in Asia

Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President Kos Biotechnology Partners ("Kos"), a global ...

October 28, 2026 | Wednesday | News
Ambrose Healthcare Acquires AM-Pharma in Deal Worth Up to €161 Million

Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the agreement, AM-Pharma's shareholders are...

October 21, 2026 | Wednesday | News
FDA Approves Roche’s Enspryng for Adults with Thyroid Eye Disease

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...

October 19, 2026 | Monday | News
FDA Accepts Bayer’s KERENDIA Application for CKD Without Diabetes

The supplemental New Drug Application (sNDA) was supported by results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adult...

October 09, 2026 | Friday | News
CHARM Therapeutics Begins Phase I/II Trial of CHM-029 for Acute Myeloid Leukaemia

CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia...

October 08, 2026 | Thursday | News
Cerevance Reports Positive Phase 3 Results for Solengepras in Parkinson’s Disease

Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements ...

October 08, 2026 | Thursday | News
Korro Bio Begins Phase 1/2 Trial of KRRO-121 for Urea Cycle Disorders

Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background  Administered...

October 07, 2026 | Wednesday | News
CSL and Alentis Partner to Develop Lixudebart for Rare Kidney and Liver Diseases

CSL and Alentis Therapeutics announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which ha...

October 06, 2026 | Tuesday | News
AnnJi Advances AJ201 into Phase 3 Trial for Kennedy’s Disease

AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...

October 06, 2026 | Tuesday | News
Johnson & Johnson Reports Sustained Survival Benefits With TECVAYLI and Daratumumab in Multiple Myeloma

Johnson & Johnson, a worldwide leader in multiple myeloma, announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and...

September 25, 2026 | Friday | News
InnoCare Pharma and Eli Lilly Partner to Develop New Medicines Across Five Targets

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Company has entered ...

September 25, 2026 | Friday | News
Silo Pharma Receives USPTO Notice of Allowance for SPC-15 PTSD Therapeutic

Silo Pharma (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug del...

September 21, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close